Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 05 tags : Therapy save search
Global Cancer Therapies Market to Reach $204.2 Billion by 2024
Published: 2021-08-05 (Crawled : 15:15) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.42%
H: 0.31%
C: 0.13%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -0.09%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.69%
H: 0.37%
C: 0.34%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.31%
H: 0.85%
C: 0.35%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.36%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 1.48%
H: 0.46%
C: 0.43%
cancer therapy
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
Published: 2021-08-05 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.0%
H: 0.13%
C: 0.09%
collaboration cancer research announces collaboration therapy
Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
Published: 2021-08-05 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.05%
H: 0.23%
C: 0.09%
risk therapy phase 3 trial keytruda
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.